Red Flags Detected
- Going Concern (new) — Substantial doubt disclosed due to cash runway ending Q3 2026 and insufficient capital to fund drug development plans.
- Material Weakness (improved) — Stock-based compensation control deficiency identified in 2024 audit was remediated by September 30, 2025 through hiring GAAP-expert personnel and implementing formal controls.
Partial Analysis Warning
One or more filing sections could not be analyzed because the AI response was not valid JSON. The rest of the report was generated normally, but this report may omit material changes from:
- Business: Section analysis failed; admin notified.
Turn Therapeutics flags going concern, $5M cash runs to Q3 2026, needs $60-65M for trials
Filed March 31, 2026 · Period ending December 31, 2025 · ~2 min read
5 material changes detected in this filing.
Create a free account to read the full summary — it takes 30 seconds.
Partner
Trade TTRX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 3, 2026 11:56 PM